Literature DB >> 19796074

Allele-selective inhibition of mutant huntingtin by peptide nucleic acid-peptide conjugates, locked nucleic acid, and small interfering RNA.

Jiaxin Hu1, Masayuki Matsui, David R Corey.   

Abstract

The ability to inhibit expression of a mutant allele while retaining expression of a wild-type protein might provide a useful approach to treating Huntington's Disease (HD) and other inherited pathologies. The mutant form of huntingtin (HTT), the protein responsible for HD, is encoded by an mRNA containing an expanded CAG repeat. We demonstrate that peptide nucleic acid conjugates and locked nucleic acids complementary to the CAG repeat selectively block expression of mutant HTT. The selectivity of inhibition is at least as good as that shown by a small interfering RNA targeted to a deletion polymorphism. Our data suggest that antisense oligomers are promising subjects for further development as an anti-HD therapeutic strategy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19796074      PMCID: PMC3908448          DOI: 10.1111/j.1749-6632.2009.04975.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  28 in total

1.  Antisense-mediated down-regulation of the human huntingtin gene.

Authors:  R J Boado; A Kazantsev; B L Apostol; L M Thompson; W M Pardridge
Journal:  J Pharmacol Exp Ther       Date:  2000-10       Impact factor: 4.030

2.  Trinucleotide repeats that expand in human disease form hairpin structures in vitro.

Authors:  A M Gacy; G Goellner; N Juranić; S Macura; C T McMurray
Journal:  Cell       Date:  1995-05-19       Impact factor: 41.582

3.  A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats.

Authors:  B Kremer; P Goldberg; S E Andrew; J Theilmann; H Telenius; J Zeisler; F Squitieri; B Lin; A Bassett; E Almqvist
Journal:  N Engl J Med       Date:  1994-05-19       Impact factor: 91.245

Review 4.  LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA.

Authors:  Birte Vester; Jesper Wengel
Journal:  Biochemistry       Date:  2004-10-26       Impact factor: 3.162

5.  Trinucleotide repeat length instability and age of onset in Huntington's disease.

Authors:  M Duyao; C Ambrose; R Myers; A Novelletto; F Persichetti; M Frontali; S Folstein; C Ross; M Franz; M Abbott
Journal:  Nat Genet       Date:  1993-08       Impact factor: 38.330

6.  RNA structure of trinucleotide repeats associated with human neurological diseases.

Authors:  Krzysztof Sobczak; Mateusz de Mezer; Gracjan Michlewski; Jacek Krol; Wlodzimierz J Krzyzosiak
Journal:  Nucleic Acids Res       Date:  2003-10-01       Impact factor: 16.971

7.  Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset.

Authors:  Nancy S Wexler; Judith Lorimer; Julie Porter; Fidela Gomez; Carol Moskowitz; Edith Shackell; Karen Marder; Graciela Penchaszadeh; Simone A Roberts; Javier Gayán; Denise Brocklebank; Stacey S Cherny; Lon R Cardon; Jacqueline Gray; Stephen R Dlouhy; Sandra Wiktorski; Marion E Hodes; P Michael Conneally; Jack B Penney; James Gusella; Jang-Ho Cha; Michael Irizarry; Diana Rosas; Steven Hersch; Zane Hollingsworth; Marcy MacDonald; Anne B Young; J Michael Andresen; David E Housman; Margot Mieja De Young; Ernesto Bonilla; Theresa Stillings; Americo Negrette; S Robert Snodgrass; Maria Dolores Martinez-Jaurrieta; Maria A Ramos-Arroyo; Jacqueline Bickham; Juan Sanchez Ramos; Frederick Marshall; Ira Shoulson; Gustavo J Rey; Andrew Feigin; Norman Arnheim; Amarilis Acevedo-Cruz; Leticia Acosta; Jose Alvir; Kenneth Fischbeck; Leslie M Thompson; Angela Young; Leon Dure; Christopher J O'Brien; Jane Paulsen; Adam Brickman; Denise Krch; Shelley Peery; Penelope Hogarth; Donald S Higgins; Bernhard Landwehrmeyer
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-01       Impact factor: 11.205

8.  Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes.

Authors:  J Nasir; S B Floresco; J R O'Kusky; V M Diewert; J M Richman; J Zeisler; A Borowski; J D Marth; A G Phillips; M R Hayden
Journal:  Cell       Date:  1995-06-02       Impact factor: 41.582

9.  Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide.

Authors:  P E Nielsen; M Egholm; R H Berg; O Buchardt
Journal:  Science       Date:  1991-12-06       Impact factor: 47.728

10.  Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs.

Authors:  Jiaxin Hu; Masayuki Matsui; Keith T Gagnon; Jacob C Schwartz; Sylvie Gabillet; Khalil Arar; Jun Wu; Ilya Bezprozvanny; David R Corey
Journal:  Nat Biotechnol       Date:  2009-05-03       Impact factor: 54.908

View more
  24 in total

Review 1.  Allele-selective inhibition of trinucleotide repeat genes.

Authors:  Masayuki Matsui; David R Corey
Journal:  Drug Discov Today       Date:  2012-01-18       Impact factor: 7.851

2.  Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism.

Authors:  Jiaxin Hu; Jing Liu; David R Corey
Journal:  Chem Biol       Date:  2010-11-24

3.  A natural antisense transcript at the Huntington's disease repeat locus regulates HTT expression.

Authors:  Daniel W Chung; Dobrila D Rudnicki; Lan Yu; Russell L Margolis
Journal:  Hum Mol Genet       Date:  2011-06-13       Impact factor: 6.150

Review 4.  Gene therapy in mouse models of huntington disease.

Authors:  Amber L Southwell; Paul H Patterson
Journal:  Neuroscientist       Date:  2011-04       Impact factor: 7.519

5.  Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice.

Authors:  Mireia Garriga-Canut; Carmen Agustín-Pavón; Frank Herrmann; Aurora Sánchez; Mara Dierssen; Cristina Fillat; Mark Isalan
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-10       Impact factor: 11.205

Review 6.  Huntington's Disease-Update on Treatments.

Authors:  Kara J Wyant; Andrew J Ridder; Praveen Dayalu
Journal:  Curr Neurol Neurosci Rep       Date:  2017-04       Impact factor: 5.081

7.  Allele-selective inhibition of ataxin-3 (ATX3) expression by antisense oligomers and duplex RNAs.

Authors:  Jiaxin Hu; Keith T Gagnon; Jing Liu; Jonathan K Watts; Jeja Syeda-Nawaz; C Frank Bennett; Eric E Swayze; John Randolph; Jyoti Chattopadhyaya; David R Corey
Journal:  Biol Chem       Date:  2011-02-07       Impact factor: 3.915

8.  Cellular localization and allele-selective inhibition of mutant huntingtin protein by peptide nucleic acid oligomers containing the fluorescent nucleobase [bis-o-(aminoethoxy)phenyl]pyrrolocytosine.

Authors:  Jiaxin Hu; David W Dodd; Robert H E Hudson; David R Corey
Journal:  Bioorg Med Chem Lett       Date:  2009-09-06       Impact factor: 2.823

9.  Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity.

Authors:  Xin Sun; Leonard O Marque; Zachary Cordner; Jennifer L Pruitt; Manik Bhat; Pan P Li; Geetha Kannan; Ellen E Ladenheim; Timothy H Moran; Russell L Margolis; Dobrila D Rudnicki
Journal:  Hum Mol Genet       Date:  2014-07-04       Impact factor: 6.150

10.  Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat.

Authors:  Keith T Gagnon; Hannah M Pendergraff; Glen F Deleavey; Eric E Swayze; Pierre Potier; John Randolph; Eric B Roesch; Jyoti Chattopadhyaya; Masad J Damha; C Frank Bennett; Christophe Montaillier; Marc Lemaitre; David R Corey
Journal:  Biochemistry       Date:  2010-11-08       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.